New hope for myeloma: phase 3 trial pits JNJ-79635322 against current drug
NCT ID NCT07518186
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study compares a new injectable drug, JNJ-79635322, to an existing one, teclistamab, in about 700 people with multiple myeloma that has returned after 1 to 3 prior treatments. The goal is to see which drug works better at shrinking tumors and delaying disease progression. Participants must have had prior therapy including an anti-CD38 antibody and lenalidomide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-79635322 (injection)
What this could lead to
If it works, this could offer a more effective treatment option for people with multiple myeloma that has returned after initial therapies.
What could go wrong
This is an early-stage comparison; the new drug may not prove better than the existing one, and side effects are possible. Results are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carmel Medical Center
RECRUITINGHaifa, 3436212, Israel
-
China Medical University Hospital
RECRUITINGTaichung, 40447, Taiwan
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
-
Medipol Mega University Hospital
RECRUITINGIstanbul, 34214, Turkey (Türkiye)
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
-
Rambam Med.Center - Hematology Institute
RECRUITINGHaifa, 3109601, Israel
-
Taichung Veterans General Hospital
RECRUITINGTaichung, 40705, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan